Asosiy kontentga oʻtish
Maqola

Kimyoterapiyadan keyin bolalarda neyrotoksiklikning qon zardobidagi biomarkerlari (IL-6, TNF-α, NSE, GFAP) va ularning neyrokognitiv körsatkiçlar hamda hayot sifati bilan boğliqligi

Мая СамандароваTashkent State Medical UniversityYokutkhon MadjidovaTashkent State Medical UniversityЁкутхон МаджидоваYokutxon MadjidovaTashkent State Medical University
2026ru
ABI

Annotatsiya

Objective. To assess serum levels of inflammatory (IL-6, TNF-α), neuronal (NSE), and glial (GFAP) biomarkers in children following chemotherapy for oncohematological diseases and their associations with neurocognitive outcomes, MRI findings, and quality of life. Materials and Methods. Biomarker levels were measured in 30 of 111 examined patients (ALL, n = 15; AML, n = 10; lymphoma, n = 5) aged 3–18 years. Intelligence (WISC), executive functions (BRIEF), quality of life (PedsQL 4.0), and brain MRI findings were assessed. Statistical methods included Spearman correlation analysis, regression analysis, and ROC analysis. Results. All biomarker levels exceeded the reference limits in every patient and were highest in the AML group (GFAP: 412.8 ± 55.9 pg/mL; TNF-α: 111.5 ± 17.5 pg/mL; IL-6: 63.6 ± 11.2 pg/mL; p < 0.01). Biomarker levels did not correlate with IQ (all p > 0.1). They were strongly inversely associated with PedsQL scores (ρ ranging from −0.45 to −0.68), and IL-6 and TNF-α identified impaired quality of life with an AUC of 0.944. However, the association lost statistical significance after adjustment for diagnosis (p = 0.19). GFAP correlated with the number of MRI findings (ρ = 0.39; p = 0.035). Conclusion. Elevated inflammatory and glial biomarker levels reflect the intensity of the neurotoxic burden, which is greatest in AML, and are associated with poorer quality of life. However, in this sample, they did not predict intellectual decline independently of diagnosis.

Hali tarjima qilinmagan

Identifikatorlar

Iqtiboslar va manbalar